

July 22, 1969

Dr. Edgar Grunwaldt
Geigy Pharmaceuticals
Ardsley, New York

Dear Ed,

As I reported earlier, we have had one adverse drug experience in the ketimipramine-imipramine study. The patient developed a severe agranulocytosis after imipramine. He responded to treatment, and was discharged "recovered" for this episode. A contributing factor may have been the presence of a neoplasm of the nasopharynx - for which he had been previously treated, and is now being treated.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp

enc.